Indoline Derivatives for Disease Treatment
Summary
The USPTO granted patent US12599584B2 to Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. covering indoline derivatives and pharmaceutical compositions for treating diseases associated with oxidative stress, immune response, NO release, and pro-inflammatory cytokines. The patent names Marta Weinstock-Rosin, Abraham Nudelman, and Shani Zeeli as inventors and was filed on January 19, 2017. This grant establishes intellectual property protection for the therapeutic applications of these indoline compounds.
What changed
The USPTO granted patent US12599584B2 to Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. for indoline derivatives and pharmaceutical compositions for treating diseases linked to oxidative stress, immune response, nitric oxide release, and pro-inflammatory cytokine activity. The patent claims priority to a filing date of January 19, 2017.
Pharmaceutical companies and biotechnology firms developing competing therapeutic products in this chemical space should monitor this patent estate to assess potential freedom-to-operate considerations or licensing opportunities. The intellectual property protection granted may affect competitive positioning in the anti-inflammatory and oxidative stress therapeutic market.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Indoline derivatives, compositions comprising them and uses thereof
Grant US12599584B2 Kind: B2 Apr 14, 2026
Assignee
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
Inventors
Marta Weinstock-Rosin, Abraham Nudelman, Shani Zeeli
Abstract
The present invention is directed to indoline derivatives and salts thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders associated with at least one of oxidative stress, an immune response, release of NO and release of pro-inflammatory cytokine.
CPC Classifications
A61K 31/405 A61K 31/4545 A61K 31/4045 C07D 208/08 C07D 208/14 C07D 208/18 C07D 209/08 C07D 209/14 C07D 209/18 A61P 25/00 A61P 29/00
Filing Date
2017-01-19
Application No.
16071092
Claims
1
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.